Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.

Favipiravir (FAV; T-705) has been approved for use as an anti-influenza therapeutic and has reports against a wide range of viruses (e.g., Ebola virus, rabies and norovirus). Most recently FAV has been reported to demonstrate activity against SARS-CoV-2. Repurposing opportunities have been intensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Curley, Paul, Neary, Megan, Arshad, Usman, Tatham, Lee, Pertinez, Henry, Box, Helen, Rajoli, Rajith KR, Valentijn, Anthony, Sharp, Joanne, Rannard, Steve P, Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872349/
https://www.ncbi.nlm.nih.gov/pubmed/33564761
http://dx.doi.org/10.1101/2021.02.03.429628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872349/
https://www.ncbi.nlm.nih.gov/pubmed/33564761
http://dx.doi.org/10.1101/2021.02.03.429628

Ejemplares similares